Annals of Surgical Oncology

, Volume 26, Issue 5, pp 1503–1511 | Cite as

Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection

  • Brian A. BooneEmail author
  • Mazen S. Zenati
  • Caroline Rieser
  • Ahmad Hamad
  • Amr Al-abbas
  • Amer H. Zureikat
  • Melissa E. Hogg
  • Matthew D. Neal
  • Herbert J. ZehIII
Pancreatic Tumors



Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perioperative period for patients undergoing surgical resection. However, data are lacking for patients undergoing neoadjuvant treatment followed by resection, who may have a unique risk of VTE because of exposure to both chemotherapy and surgery.


The study included patients with PDA who underwent neoadjuvant therapy followed by surgery from 2007 to June 2017. Development of VTE was evaluated from the start of treatment through the 90-day postoperative period. Risk factors including demographic, treatment, and laboratory variables were evaluated.


The study investigated 426 patients receiving neoadjuvant therapy before surgical resection. Of these patients, 20% had a VTE within 90 days postoperatively (n = 87), and 70% of the VTE occurred during the postoperative period. The VTE included pulmonary embolism (30%), deep vein thrombosis (33%), and thrombosis of the portal vein (PV)/superior mesenteric vein (SMV) (40%). A pretreatment hemoglobin level lower than 10 g/dL and a platelet count higher than 443 were independently associated with VTE during neoadjuvant treatment. The independent predictors of postoperative VTE were a body mass index higher than 35 kg/m2, a preoperative platelet-to-lymphocyte ratio higher than 260, resection with distal pancreatectomy with celiac axis resection/total pancreatectomy, PV/SMV resection, and longer operative times. Development of VTE was associated with worse overall and disease-free survival and an independent predictor of survival and decreased likelihood of receiving adjuvant chemotherapy.


Venous thromboembolism during neoadjuvant therapy and the subsequent perioperative period is common and has a significant impact on outcome. Further study into novel thromboprophylaxis measures or protocols during neoadjuvant treatment and the perioperative period is warranted.



There are no conflicts of interest.

Supplementary material

10434_2018_7148_MOESM1_ESM.docx (42 kb)
Supplementary material 1 (DOCX 34 kb)


  1. 1.
    Woei AJFJ, Tesselaar ME, Garcia Rodriguez P, Romijn FP, Bertina RM, Osanto S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer. 2016;115:332–8.CrossRefGoogle Scholar
  2. 2.
    Boone BA, Miller-Ocuin JL, Doerfler WR, Ellis JT, Lotze MT, Neal MD, Zeh HJ. Neutrophil extracellular traps promote hypercoagulability in pancreatic cancer through release of tissue factor and platelet aggregation. Ann Surg Oncol. 2017;S1:S110.Google Scholar
  3. 3.
    Pinzon R, Drewinko B, Trujillo JM, Guinee V, Giacco G. Pancreatic carcinoma and Trousseau’s syndrome: experience at a large cancer center. J Clin Oncol. 1986;4:509–14.CrossRefGoogle Scholar
  4. 4.
    Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood. 1983;62:14–31.Google Scholar
  5. 5.
    Kruger S, Haas M, Burkl C, et al. Incidence, outcome, and risk stratification tools for venous thromboembolism in advanced pancreatic cancer: a retrospective cohort study. Thromb Res. 2017;157: 9–15.CrossRefGoogle Scholar
  6. 6.
    Petterson TM, Marks RS, Ashrani AA, Bailey KR, Heit JA. Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res. 2015;135:472–8.CrossRefGoogle Scholar
  7. 7.
    Molena D, Mungo B, Stem M, Feinberg RL, Lidor AO. Prevalence, impact, and risk factors for hospital-acquired conditions after major surgical resection for cancer: a NSQIP analysis. J Gastrointest Surg. 2015;19:142–51; discussion 151.CrossRefGoogle Scholar
  8. 8.
    Tzeng CW, Katz MH, Lee JE, Fleming JB, Pisters PW, Vauthey JN, Aloia TA. Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients. HPB Oxf. 2014;16:373–83.CrossRefGoogle Scholar
  9. 9.
    Ramanathan R, Mason T, Wolfe LG, Kaplan BJ. Predictors of short-term readmission after pancreaticoduodenectomy. J Gastrointest Surg. 2018;22:998–1006.CrossRefGoogle Scholar
  10. 10.
    Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular-weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33:2028–34.CrossRefGoogle Scholar
  11. 11.
    Shaib W, Deng Y, Zilterman D, Lundberg B, Saif MW. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res. 2010;30:4261–4.Google Scholar
  12. 12.
    Ishigaki K, Nakai Y, Isayama H, et al. Thromboembolisms in advanced pancreatic cancer: a retrospective analysis of 475 patients. Pancreas. 2017;46:1069–75.CrossRefGoogle Scholar
  13. 13.
    Du L, Wang-Gillam A. Trends in neoadjuvant approaches in pancreatic cancer. J Natl Compr Cancer Netw. 2017;15:1070–7.CrossRefGoogle Scholar
  14. 14.
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.CrossRefGoogle Scholar
  15. 15.
    Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251:344–50.CrossRefGoogle Scholar
  16. 16.
    Krepline AN, Christians KK, George B, et al. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? J Surg Oncol. 2016;114:581–6.CrossRefGoogle Scholar
  17. 17.
    Larsen AC, Brondum Frokjaer J, Wishwanath Iyer V, et al. Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors. J Thromb Haemost. 2015;13:555–62.CrossRefGoogle Scholar
  18. 18.
    Sogaard KK, Schmidt M, Pedersen L, Horvath-Puho E, Sorensen HT. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 2014;130:829–36.CrossRefGoogle Scholar
  19. 19.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.CrossRefGoogle Scholar
  20. 20.
    Menapace LA, Khorana AA. The role of thromboprophylaxis in cancer patients: emerging data. Curr Opin Hematol. 2010;17:450–6.CrossRefGoogle Scholar
  21. 21.
    Munoz Martin AJ, Garcia Alfonso P, Ruperez Blanco AB, Perez Ramirez S, Blanco Codesido M, Martin Jimenez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model. Clin Transl Oncol. 2014;16:927–30.CrossRefGoogle Scholar
  22. 22.
    Beal EW, Tumin D, Chakedis J, et al. Identification of patients at high risk for post-discharge venous thromboembolism after hepato-pancreato-biliary surgery: which patients benefit from extended thromboprophylaxis? HPB Oxf. 2018;20:621–30.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Brian A. Boone
    • 1
    • 2
    Email author
  • Mazen S. Zenati
    • 1
  • Caroline Rieser
    • 1
  • Ahmad Hamad
    • 1
  • Amr Al-abbas
    • 1
  • Amer H. Zureikat
    • 1
  • Melissa E. Hogg
    • 1
  • Matthew D. Neal
    • 1
  • Herbert J. ZehIII
    • 1
    • 3
  1. 1.Department of SurgeryUniversity of PittsburghPittsburghUSA
  2. 2.Division of Surgical Oncology, Department of SurgeryWest Virginia UniversityMorgantownUSA
  3. 3.Department of SurgeryUT SouthwesternDallasUSA

Personalised recommendations